🔥 Friday 16 October 2026 Fri, 16 Oct 2026

Genetic Signatures says its existing directors will resign if BCAL nominees become a majority after the 28 October EGM. The company is also demanding clarity on whether BCAL intends to merge with GSS, pointing to the stark difference between the two companies’ cash runways.

Matsa Resources has flagged material uncertainty over its ability to continue as a going concern after a $39.4 million FY2026 loss, negative net assets and a dispute that halted Devon mining. A pending $55 million AngloGold transaction could provide substantial liquidity, but most of the cash remains tied to completion and debt repayment.

Ramelius Resources has converted its Spartan acquisition into early production at Dalgaranga, a 79% lift in Ore Reserves and a pathway to more than 600,000 ounces a year by FY30. The trade-off is a much larger execution program, with Mt Magnet expansion and Rebecca-Roe development still ahead.

Bounty Oil & Gas reported a larger FY2026 loss and weaker production, while reshaping its portfolio around Queensland oil development and a proposed deepwater Liberia entry. The strategy is backed by fresh equity, but depends on further funding, regulatory progress and a production sharing contract that has not yet been finalised.

Neometals has cut its annual loss and sharpened its portfolio, but Deloitte has warned of a material uncertainty over the company’s ability to continue as a going concern. The miner says it may need about A$5 million in additional funding from December while pursuing unpaid placement proceeds from Omaha Value Holdings.

Aeris Resources finished FY26 with $178.5 million in net profit, $290.2 million of EBITDA and no material debt, while Tritton’s copper reserves expanded sharply. The challenge now shifts from rebuilding the balance sheet to converting a larger resource base into sustained production.

Minerals Exploration has expanded its New Zealand exploration pipeline after broad gold intersections at Jubilee South and high-grade tungsten results at Invincible. The next phase is more ambitious, but A$1.96 million in cash covers only 1.91 quarters at the latest spending rate.

Noxopharm has completed its first-in-human safety trial for SOF-SKN and advanced the wider Sofra platform, but its annual report flags a material uncertainty over funding. The biotech ended June with A$293,573 in cash, net liabilities of A$3.65 million and a need for additional capital.

Associate Global Partners lifted funds under management 20% to $1.672 billion in FY2026, powered by $172 million of net inflows and stronger WCM performance. The funds platform remains loss-making, but adjusted losses narrowed and post-year-end inflows began strongly.

Mesoblast has reported a sharp first-quarter commercial improvement, with Ryoncil revenue rising 44% and net operating cash spend falling 85% year on year. The company ended September with US$99 million in cash, although the figures remain preliminary.

Macro Metals has completed its A$1 million acquisition of the Yandi South Iron Ore Project, receiving previously undisclosed geological data that identifies nine additional prospects. Surface samples returned iron grades as high as 66.2%, but drilling is still needed to establish continuity, thickness and depth.

Euroz Hartleys has appointed Alan Logan as CEO and unveiled a reshaped board as it prepares to complete the BMO transaction and focus on private wealth. Jay Hughes will return as chairman, while two current advisers will join the board as executive directors.

Gulf Stream Energy has identified oil in two separate sandstone zones at its Zydeco project in Louisiana, although the result is based solely on wireline logs and has not yet been flow-tested. The well also retains access to the undrilled Upper Tweedle gas and condensate target.

Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.

Helloworld Travel expects FY27 Underlying EBITDA of $78 million to $84 million, including a $14 million contribution from its Crown Currency Exchange acquisition. Forward bookings are running about 10% ahead, although first-quarter trading was broadly flat and the guidance remains partly unaudited.

St Barbara reported a $489.7 million FY26 statutory profit, but almost all of it came from the deconsolidation of New Simberi Gold rather than recurring operations. The annual report also confirms a debt-free balance sheet, a 5-cent fully franked dividend and a portfolio moving from transaction-making to project delivery.

Manuka Resources says Wonawinta has reached full gold processing capacity, with its second gold delivery now on route to the ABC refinery. The company plans to shift from fortnightly to weekly sales before commissioning the silver circuit in December.

Cooper Metals has launched a fully underwritten 1-for-4 entitlement issue at 7.5 cents a share to raise up to $2.695 million before costs. Most of the proceeds are earmarked for the Chalterra copper project and its acquisition, while shareholders who do not participate face potential dilution.

Austco Healthcare is pursuing its largest acquisition to date, combining a real-time monitoring software business with an aged care nurse call specialist in a deal worth up to an estimated $19.3 million. The transactions would add debt, recurring revenue and integration risk as the company expands beyond its core Tacera platform.

Aurum Resources has reported further high-grade gold at its BST1 deposit in Côte d’Ivoire, including mineralisation beyond the current resource that remains open at depth. The results will feed an updated Boundiali resource estimate due by the end of October and a definitive feasibility study targeted for late 2026.

HMC Capital delivered FY26 operating earnings in line with guidance while statutory results swung to a $111.6 million loss. The alternative asset manager is targeting at least 35 cents of underlying earnings per share and a 15 cents dividend in FY27.

Latrobe Magnesium says its Phase 1B demonstration plant is 95% installed and 35% commissioned, keeping first magnesium metal crowns above 98% purity on track for the end of 2026. The operational advance comes alongside a tight funding position, an extended A$3.4 million entitlement offer and an ambitious South Carolina expansion plan.

Resimac Group delivered a stronger FY26, with normalised NPAT up 26% to $49.9 million and total assets under management reaching a record $16.5 billion. The result supports higher ordinary dividends, but the lender is still managing asset finance run-off, ASIC hardship proceedings and longer-term funding risks.

Weebit Nano has begun silicon validation with a second customer whose chip is running software from integrated ReRAM, marking another step towards potential production in 2027. The company also added two AI customers, advanced qualification work and ended the quarter with A$164.2 million in cash.